Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer

[1]  P. Jänne,et al.  Acquired Resistance to KRASG12C Inhibition in Cancer. , 2021, The New England journal of medicine.

[2]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[3]  X. Le.  Heterogeneity in MET-Aberrant NSCLC. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  F. Blackhall,et al.  Mechanisms of Resistance to KRASG12C Inhibitors , 2021, Cancers.

[5]  N. Reinmuth,et al.  Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  A. Shaw,et al.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.

[7]  B. Taylor,et al.  Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib , 2020, Clinical Cancer Research.

[8]  M. Mino‐Kenudson,et al.  Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Desai,et al.  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. , 2020, The New England journal of medicine.

[10]  H. Groen,et al.  Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[11]  J. Blay,et al.  Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[12]  Ying Cheng,et al.  Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. , 2020, The Lancet. Respiratory medicine.

[13]  A. Shaw,et al.  Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer. , 2020 .

[14]  A. Mansfield,et al.  Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. , 2020, Journal of Clinical Oncology.

[15]  D. Planchard,et al.  Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. , 2020, European journal of cancer.

[16]  M. Lawrence,et al.  MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer , 2020, Clinical Cancer Research.

[17]  L. Sequist,et al.  Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. , 2020, The Lancet. Oncology.

[18]  M. Ahn,et al.  TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  D. Pe’er,et al.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer , 2020, Clinical Cancer Research.

[20]  A. Drilon,et al.  Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[21]  Jeffrey W. Clark,et al.  Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration , 2019, Nature Medicine.

[22]  Y. Wu,et al.  INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study , 2019, Annals of Oncology.

[23]  J. Thiery,et al.  Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer , 2019, Clinical Cancer Research.

[24]  Amanda R. Kulick,et al.  Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation , 2019, Nature Medicine.

[25]  S. Matsumoto,et al.  Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer. , 2019, Clinical lung cancer.

[26]  M. Ahn,et al.  SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib. , 2019, Journal of Clinical Oncology.

[27]  Summer S. Han,et al.  Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. , 2019, Lung cancer.

[28]  M. Kris,et al.  Characteristics and Outcomes of Patients With Metastatic KRAS‐Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  C. Paweletz,et al.  Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib , 2018, JAMA oncology.

[30]  Y. Ohe,et al.  Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Charles M. Rudin,et al.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer , 2018, Clinical Cancer Research.

[32]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  J. Barrett,et al.  Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Barrett,et al.  Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  S. Digumarthy,et al.  Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. , 2018, Cancer discovery.

[36]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[37]  J. Roth,et al.  Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC , 2018, Clinical Cancer Research.

[38]  M. Ahn,et al.  Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. , 2018, Journal of Clinical Oncology.

[39]  G. O’Kane,et al.  Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials. , 2018, Current oncology.

[40]  G. Rossi,et al.  BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. , 2018, Cancer treatment reviews.

[41]  Ying Cheng,et al.  Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer , 2018 .

[42]  G. Scagliotti,et al.  Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? , 2017, Cancer treatment reviews.

[43]  Yi-long Wu,et al.  OA 09.06 A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC , 2017 .

[44]  A. Shaw,et al.  Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial , 2017, The Lancet. Oncology.

[45]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[46]  U. Stammberger,et al.  The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. , 2017, American journal of cancer research.

[47]  L. Horn,et al.  Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR‐Mutated Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  A. Drilon,et al.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.

[49]  Serafino Pantano,et al.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[50]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[51]  K. O'Byrne,et al.  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Salgia,et al.  Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. , 2016, Cancer letters.

[53]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[54]  S. Ou,et al.  High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. , 2016, Lung cancer.

[55]  H. Ji,et al.  Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors , 2016, Clinical Cancer Research.

[56]  K. Kiura,et al.  Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. , 2016, Cancer research.

[57]  T. Mok,et al.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis , 2016, Clinical Cancer Research.

[58]  F. Cappuzzo,et al.  cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance , 2015, Cancers.

[59]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[60]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[61]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[62]  A. Iafrate,et al.  Anchored multiplex PCR for targeted next-generation sequencing , 2014, Nature Medicine.

[63]  K. Nishio,et al.  Targeting MET Amplification as a New Oncogenic Driver , 2014, Cancers.

[64]  Toyokawa Gouji,et al.  Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[65]  N. Reguart,et al.  Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. , 2014, Cancer treatment reviews.

[66]  C. Rudin,et al.  Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[67]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[69]  P. Lambin,et al.  Non-small cell lung cancer, locally advanced , 2012 .

[70]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[71]  T. Nakagawa,et al.  Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer , 2012, Clinical Cancer Research.

[72]  M. Loda,et al.  Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. , 2010, The American journal of pathology.

[73]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[74]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2009, Clinical Cancer Research.

[75]  Morag Park,et al.  Crosstalk in Met receptor oncogenesis. , 2009, Trends in cell biology.

[76]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  A. Marchetti,et al.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Naujokas,et al.  Pak4, a Novel Gab1 Binding Partner, Modulates Cell Migration and Invasion by the Met Receptor , 2009, Molecular and Cellular Biology.

[79]  Y. Yatabe,et al.  Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.

[80]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[81]  David I. Smith,et al.  A role for common fragile site induction in amplification of human oncogenes. , 2002, Cancer cell.

[82]  R. Jove,et al.  Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis , 2002, Oncogene.

[83]  C. Maroun,et al.  The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase , 2000, Molecular and Cellular Biology.

[84]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[85]  W. Birchmeier,et al.  Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses , 2000, The Journal of cell biology.

[86]  L. Buday,et al.  Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. , 1999, Cellular signalling.

[87]  W. Birchmeier,et al.  Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis , 1996, Nature.

[88]  D. Kamikura,et al.  Pathways Downstream of Shc and Grb2 Are Required for Cell Transformation by the Tpr-Met Oncoprotein* , 1996, The Journal of Biological Chemistry.

[89]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[90]  G. Michalopoulos,et al.  Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. , 1991, Oncogene.

[91]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[92]  C. Cooper,et al.  Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.

[93]  C. Schumann,et al.  A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[94]  M. Lawrence,et al.  Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. , 2018, Cancer discovery.

[95]  A. Drilon,et al.  Targeting MET in Lung Cancer: Will Expectations Finally Be MET? , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[96]  S. Kimura,et al.  Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. , 2012, Lung cancer.

[97]  P. Jänne,et al.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.